You know, this continual debating of TPGS v TPM is such a tired waste of time imo.
Been seeing it go on and on and round and round and really, does it add any value at all or is it just a continual distraction of what should really be discussed.
We all know by now the opinion and views of some and so be it....they r entitled to them just as others are entitled to seeing positives but to engage the never ending debate is pointless.
The Co will either prove something up or it won't...simple as that, and the discussion focus should be on what merits, opportunities or shortcomings TPM (and Management) has to get to market.
We all also know about missed or botched opps, poor decisions etc so again, why rehash old news.
In saying the above, I have been reading some recent articles, patents and recent commercialisation of a product that....low & behold....is not TPGS yet has somehow found itself in the commercial CBD market in the so called TPGS dominated world with a pretty large global entity. The product has been around quite a long time but has recently gained traction in CBD.
Does this mean TPM is better than TPGS or this other product....no.
Does it mean there appears opportunity and a loose road map to maybe review to assist in TPM / CBD possibilities in the so called TPGS world...I believe so.
I'll preface this next section with a previous post around previous TPM CoQ10 / MCT research HERE and an independent CBD / MCT article posted previously HERE as has some relevance & parallels imo.
Whilst TPM has been around for quite a long time as well with many stalled starts, their more recent studies into CoQ10 / MCT (as well as Omega 3) showed some positives.
Does AVE have some way to go, yes. However, we have the recent promising update moving to the next level trials which the below product has also already done and is moving toward the following
Geocann is well-recognized for its substantial investments in research in order to meet the needs of the marketplace. In addition to this PK study and the stability data for its products, further investments in new PK research projects are well underway as well as toxicology studies needed to achieve self-affirmed GRAS status and plans for an application for Novel Food.
AVE needs to get to the next level and have peer reviewed just as this product has and proved itself.and if can show differentiation and improved bioavailability then who knows...sometimes partners like to jump in to assist, for a price of course and given the below global entity is moving into the CBD world, you would expect that other similar competitors will be watching and wanting their slice with a proven and patent protected formula.
Below is a snip from a Sep 2020 article HERE
So, VESIsorb started via CoQ10 / MCT progressed to other formulations and finally found increased bioavailability evidence with CBD / MCT.
From a related article Sep 20 HERE
The giants of the food industry are entering the CBD game. The first large-scale CBD production was completed and delivered earlier this month using only European resources, from cultivation and extraction of hemp biomass in Slovenia to drug delivery technology and to the production of capsules in Switzerland. Geocann and Nestlé have announced the European launch of gel formulations from a broad spectrum hemp extract using the patented VESIsorb® drug delivery system. The company takes advantage of a study on CBD published by the journal Molecules and Geocann's product safety data to build momentum.
Comments around the patents of the product HERE
“The addition of this U.S. patent strengthens the security of our innovation platform and protects our many investments in clinical research. These include both science-backed ingredients and proprietary condition-specific formulations that utilize the VESIsorb colloidal droplet delivery system,” Jesse Lopez, founder and CEO of SourceOne Global Partners commented.
From the VESIsorb site re their testing HERE
Geocann is proud to announce that the peer-reviewed journal, Molecules, has published the results of a double-blind, cross-over study comparing the pharmacokinetic (PK) parameters of a broad spectrum hemp extract formulated with VESIsorb® to that of the same broad spectrum hemp extract combined with medium chain triglyceride (MCT) oil. Overall, the VESIsorb® formulation showed statistically significant improvements for all measured pharmacokinetic parameters, including maximal plasma CBD concentration (Cmax), area under the curve (AUC), and time to peak absorption (Tmax).
“It is well-known that CBD and cannabinoids, in general, show limited bioavailability due to their lipophilicity and extensive first-pass metabolism,” said Marc Weder, Chief Scientific Officer. “The results of our study demonstrate VESIsorb® technology mitigated this effect and also significantly improved PK performance compared to standard industry practices of combining MCT oil with broad spectrum hemp extract in an effort to improve bioavailability. The VESIsorb® formulation delivered a significant 440% increase in Cmax, a 285% improvement in AUC, and a dramatically shorter Tmax of one hour versus three hours compared to the broad spectrum hemp extract combined with MCT oil.”
Actual 2019 study publications HERE & HERE
Abstract
Cannabidiol (CBD), a phytocannabinoid compound of Cannabis sativa, shows limited oral bioavailability due to its lipophilicity and extensive first-pass metabolism. CBD is also known for its high intra- and inter-subject absorption variability in humans. To overcome these limitations a novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology incorporating CBD, as Hemp-Extract, was developed (SEDDS-CBD). The study objective was to evaluate the pharmacokinetic profile of SEDDS-CBD in a randomized, double-blind, cross-over design in 16 healthy volunteers under fasted conditions. As reference formulation, the same Hemp-Extract diluted with medium-chain triglycerides (MCT-CBD) was used. CBD dose was standardized to 25 mg. Pharmacokinetic parameters were analyzed from individual concentration-time curves. Single oral administration of SEDDS-CBD led to a 4.4-fold higher Cmax and a 2.85-/1.70-fold higher AUC0–8h/AUC0–24h compared to the reference formulation. Tmax was substantially shorter for SEDDS-CBD (1.0 h) compared to MCT-CBD (3.0 h). Subgroup analysis demonstrated a higher bioavailability in women compared to men. This difference was seen for MCT-CBD while SEDDS-CBD mitigated this gender effect. Overall, SEDDS-CBD showed a significant improvement for all determined pharmacokinetic parameters: increased CBD plasma values (Cmax), favorably enhanced bioavailability (AUC) and fast absorption (Tmax). No safety concerns were noted following either administration.
Patent HERE
(20min delay)